Glucosamine/chondroitin
This article was originally published in The Tan Sheet
Executive Summary
Osteoarthritis health claim would be possible based on positive results from, and subsequent NIH "authoritative statement" on, University of Utah study, Hyman, Phelps & McNamara (D.C.) partner Stephen McNamara maintains at Nutracon 2001 in San Diego July 9. Study, co-sponsored by NCCAM, is slated for completion in 2003 (1"The Tan Sheet" April 2, In Brief). ODS Director Paul Coates, PhD, calls health claim "an interesting possibility," but notes negative could lead to "authoritative statement" against ingredients
You may also be interested in...
NCCAM
Results from glucosamine/chondroitin trial in treating osteoarthritis (co-sponsored by National Institute of Arthritis & Musculoskeletal & Skin Diseases) will be available in roughly two years, NCCAM Director Stephen Straus, MD, tells House Appropriations/labor-HHS subcommittee at hearing March 28. No adverse events have been reported to date, he says. In addition, studies on effects of soy for menopause and Chinese herbal combination PC-SPES for prostate cancer are progressing and center's new PubMed database for CAM information is being visited at a promising rate, Straus notes. Subcommittee hearing was first to address NCCAM funding under new Chair Ralph Regula (R-Ohio), who replaced six-year former Chair John Porter (R-Ill.) following his retirement
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands